HC Wainwright & Co. Reiterates Buy on Rani Therapeutics Hldgs, Maintains $9 Price Target

Benzinga · 10/18 10:52
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rani Therapeutics Hldgs (NASDAQ:RANI) with a Buy and maintains $9 price target.